This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk01: Good morning and welcome to today's ultra-industrial motion fourth quarter 2021 earnings conference call. My name is Candice and I will be your moderator for today's call. All lines will be muted during the presentation portion of the call with an opportunity for question and answer at the end. If you would like to ask a question, it is start followed by one on your telephone keypad. I would now like to pass the conference call over to our host, David Kostadian. of Sharon Murrow.
spk05: Thank you. Good morning, everyone, and welcome to the call. To help you follow management's discussion on this call, they'll be referencing slides that are posted to the ultramotion.com website under Events and Presentations in the Investor Relations section. Please turn to slide three. During the call, management will be making forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently uncertain, and investors must recognize that events could differ significantly from management's expectations. Those refer to the risks, uncertainties, and other factors described in the company's quarterly reports on Form 10-Q and any report on Form 10-K, and in the company's other filings with the U.S. Securities and Exchange Commission. Except as required by applicable law, Alter Industrial Motion Corp. does not intend to update or alter its forward-looking statements whether it's a result of new information, future events, or otherwise. On today's call, management will refer to non-GAAP diluted earnings per share, non-GAAP income from operations, non-GAAP net income, non-GAAP adjusted EBITDA, non-GAAP operating income margin, non-GAAP adjusted EBITDA margin, non-GAAP organic sales, non-GAAP gross margin, non-GAAP operating working capital, non-GAAP net debt, non-GAAP free cash flow, and non-GAAP adjusted free cash flow. These metrics exclude certain items discussed in our slide presentation and in our press release under the heading discussion of non-GAAP financial measures and any other items that management believes should be excluded when reviewing continuing operations. The reconciliations of ALTRA's non-GAAP measures to the comparable GAAP measures are available in the financial tables of the Q4 2021 financial results press release on ALTRA's website. Please turn to slide four. With me today are Chief Executive Officer Carl Christensen and Chief Financial Officer Todd Patriaca. I'll now turn the call over to Carl.
spk03: Thank you, David, and thank you for joining us today. I'd like to start this morning by recognizing the Altra team for an exceptional effort in 2021 in managing through the supply chain, inflation, and pandemic-related challenges and delivering strong financial results for the year. all while advancing our strategy to optimize Altra's position as a premier industrial company. Thanks to your contributions, we were able to continue collaborating with our customers, supporting one another, and executing strategically during this unprecedented time. I extend my sincere appreciation to all of you. And now please turn to slide five. As a result of the team's resilience, we were able to leverage positive broad-based demand trends and Altra's market position to deliver strong results in both the quarter and full year. I will start with a few highlights from the year, and Todd will get into more detail on the quarter later in the call. Our 2021 results demonstrate the resilience of Altra's diverse portfolio of highly engineered products. On a full year basis, we grew sales by 10% to $1.9 billion, which was the high end of our guidance range. We ended the year with a very strong book-to-bill ratio of 1.11 and record-level backlog of more than $800 million. This reflects both the strong underlying demand dynamics and Altra's strong market position. As a result, we're beginning 2022 with good top-line visibility, affirming as in past quarters that the underlying fundamentals of Altra's business remain intact with strong long-term growth prospects. Top line performance may be constrained by supply chain, logistics, and labor challenges. We've remained diligent in managing the factors within our control to mitigate external risks, such as availability of materials, logistics challenges, and inflation, to deliver a solid year on the bottom line. Throughout 2021, we continued to deploy Altra's world-class business system to drive improvements in many aspects of our business, including productivity, supply chain and logistics, product innovation, and organic growth. Inflation was greater than we had anticipated through the year, resulting in a cost price lag. Inflation for certain integrated circuits was particularly impactful. We implemented price increases throughout the year and will continue to implement price increases in Q1 and Q2 of 2022. We expect that the pricing actions we have taken and have announced will get us back towards our typical historical margins in Q2, provided we don't see significant additional inflation. Full year net income was $27.7 million, or 42 cents per diluted share, compared with a loss of $25.5 million, or 39 cents per share, in 2020. Non-GAAP diluted EPS for 2021 increased from $2.88 last year to a new company record of $3.22. We continue to demonstrate the strength of Altra's cash generative business model, generating $176 million in non-GAAP free cash flow in 2021. This cash generation allowed us to make continued progress delivering our balance sheet by paying down a total of $155 million of debt in 2021. We exited the year with net debt to non-GAAP adjusted EBITDA leverage ratio under 3.0 times. Now that we have reached our target leverage range, we are putting more emphasis on actively managing the portfolio to accelerate top line growth and deliver margin expansion while maintaining a strong and flexible balance sheet. On that note, please turn to slide six. I would like to highlight two recent announcements that demonstrate our progress executing on our strategy to position Altra as a premier industrial company with a focus on highly engineered products in the motion control and power transmission markets. The first is the acquisition of Nook Industries, which we closed on December 31st. With Nook, Altra is positioned to benefit from cross-selling opportunities that leverage our expanded and complementary linear motion control product offerings while also gaining strong customer relationships in strategic end markets such as medical, factory automation, and defense. We also have the opportunity to utilize Altra's scale to leverage fixed costs while capitalizing on NUC's production capacity to better satisfy increasing customer demand. We estimate Nook generated approximately $42 million in revenue in 2021, and the transaction is anticipated to be cash accretive to Ultra's earnings in 2022, excluding any one-time or acquisition-related costs. Nook is a great fit with Ultra, one that brings us not only significant potential for cost and sales synergies, but an outstanding portfolio and great group of employees. we're pleased to welcome the Nook Associates to the Altra team. And as we announced last week, we've entered into an agreement to sell our Jacob Vehicle Systems business to Cummins Incorporated for $325 million. Selling JVS aligns with our strategy to focus Altra's portfolio on highly engineered products in the motion control and power transmission markets. Upon closing the transaction, Upon closing, the transaction will substantially reduce our net debt. I'd like to take this opportunity to express my appreciation to the JVS team for their dedication and support. We believe that operating as part of Cummins will give them an opportunity to thrive with more strategically aligned ownership, and I wish them all the best. Now turning to slide seven in a review of the markets in more detail. Starting with transportation, which represented approximately 14% of our business in 2021, primarily related to JBS, Q4 sales were down double digits compared with Q4 last year, reflecting the ongoing slowdown in China for Class 8 heavy duty trucks, as well as the semiconductor chip shortage industry-wide. Moving to factory automation and specialty machinery, which represents about 12% of our business, demand in robotics, electronic assembly equipment, specialty machinery, and general factory automation machinery remained strong. Q4 sales were up high double digits compared to the prior year and down low single digits sequentially, primarily due to the typical seasonality. 2022 is shaping up to be another strong year in this market, given the positive long-term macro trends driving growth. Turf and garden, ag, and construction, which combined represents approximately 10% of our business, continue to perform well in Q4, growing high double digits year over year, with all three segments up sequentially. The fundamental growth drivers in these markets appear to be strong as we begin fiscal 2022 and our outlook remains very positive. Material handling, which represents about 8% of sales, was up double digits in Q4, driven by continuing strength across all key segments, including conveyors, forklifts, and vertical lifting systems. Long term, we remain positive about our growth prospects in material handling, driven by trends such as e-commerce, electrification, and warehousing efficiency improvements. Medical equipment, which is about 7% of our sales, was down double digits year over year. As we saw in Q3, this was in part due to a difficult comp with the prior year quarter's exceptionally strong COVID-related respirator and ventilator sales. In addition, our Q4 results reflected slowdowns in discretionary spending and CapEx as Omicron began spreading across the country. We're positive about the outlook for 2022, given the anticipated easing of COVID restrictions and return to more normal levels of spending and investment, as well as favorable prior year comps. Longer term, medical equipment remains an exciting growth market for us and is supported by several secular tailwinds. Moving into aerospace and defense, which combined is about 5% of sales, commercial aerospace was down single digits from Q4 last year, but up slightly on a sequential basis. Reflecting ongoing project timing headwinds, the defense side of the business was down double digits year over year. Our aerospace and defense business remains an important bottom line contributor with a very attractive margin profile, a strong competitive position, and high barriers to entry. A&D bookings in Q4 were strong, setting the stage for improved results in 2022. In addition, acquiring Nook Industries expands our motion control and power transmission capabilities in the A&D marketplace. Renewable energy, which represents about 4% of sales, was down double digits versus Q4 last year and sequentially. Bookings were lower both year over year and sequentially, reflecting supply chain delays and COVID-related labor market disruptions. As we saw last quarter, many of our customers are facing logistics challenges as product is being held up at ports due to global shipping delays. Looking ahead, we're expecting these headwinds to continue affecting bookings into the first half of 2022, followed by a rebound as the year progresses. Longer term, given the growth in demand for zero carbon energy solutions We continue to believe that renewables represents a very exciting growth play for Altra. And finally, distribution, which represents about 25% of sales, was up double digits from Q4 last year and up single digits sequentially. Our sales in the distribution market continue to track in line with the general industrial economy. Our bookings and book to bill for the quarter were strong, and we're anticipating a solid performance in this part of our business in 2022. Looking forward, we expect underlying economic strength and growth to continue driving strong based and market demand in 2022. Now please turn to slide eight. We begin 2022 not only extraordinarily proud of the entire Altra team, but increasingly confident that we can achieve our strategic ambition to position Altra as a premier industrial company with sustainable competitive advantages and long-term success. I'd like to conclude with a few key points. First, the resilience of Altra's diverse portfolio of highly engineered products continues to prove out as evidenced by our 2021 results that were highlighted by a 10% top-line growth, strong order rates, and record year-ending backlog. We have consistently and effectively managed the factors that we can control, like strategic pricing initiatives, supply chain management efforts, and cost controls, to deliver strong operating performance in this uncertain environment. We expect to continue to benefit from these actions as we move through 2022. Now that we have reached our targeted leverage ratio, we are positioned with greater capital deployment optionality. We will continue to actively manage the portfolio to accelerate top-line growth and deliver margin expansion while maintaining a strong and flexible balance sheet. The NUC and JVS transactions provide us with great momentum as we start the year and transition Altra into the next phase of transformative growth. And finally, we're hosting an investor day on Tuesday, March 8th, to share more on Altra's strategic roadmap. We hope that many of you can join us either virtually or in person in New York City. And with that, I'll now turn the call over to our longtime team member, recently named CFO, Todd Patriaca.
spk08: Thank you, Carl, and good morning, everyone. It's a pleasure to be here for the first time since transitioning into my new role as Ultra CFO. Please turn to slide nine. Sales for the fourth quarter were up 3.7% year over year to $470 million. Excluding foreign exchange, Q4 sales were up more than 4% year over year, reflecting continuing customer demand and a strong contribution from price, despite significant challenges with supply chains, including labor shortages, transportation issues, and material shortages. Gross margin of 33.6% was lower versus Q4 last year, primarily due to the expected slowdown in Class 8 truck-related business in China, and a difficult comparison with very strong prior year COVID-related medical equipment sales. That said, we had a record year for revenues and non-GAAP earnings per share in 2021, and we're well positioned to continue executing on our strategy. We're entering 2022 with record backlog and solid underlying market demand, despite the external challenges. We are continuing to make progress in deleveraging the balance sheet And prior to the Nook acquisition, we reduced our debt by $155 million, exceeding our 2021 pay down targets. Taking a closer look at our top line performance, price contributed 290 basis points for the quarter, and FX had a negative effect of 40 basis points. Net sales for the PTT segment, excluding FX, were up 13%. The year-over-year increase demonstrates the continued resilience of our balanced portfolio of opcos, as well as the success of our ongoing price-cost efforts within the segment. Net sales for the A&S segment, excluding FX, were down 3.6% from Q4 last year. The decline was driven by extended semiconductor lead times across many of our end markets, including automotive, as well as challenging comps for our heavy-duty truck market and medical business due to record sales into the ventilator market in the prior year. Excluding JVS, fourth quarter organic sales for the ANS segment increased 2.6% year over year. Taking a closer look at our organic sales performance by geography, organic sales were up 10.6% in Europe and 12.4% in North America, with strength across most end markets. Organic sales in Asia and the rest of the world were down 20.2% year over year, mainly due to the Class 8 truck and wind energy markets in China, as Carl discussed. Turning to look at our operating performance, non-GAAP income from operations decreased by $10 million from Q4 last year, or 12.9%, primarily due to the expected return of costs related to the exceptional cost savings actions taken during 2020, and price-cost challenges and higher operating expenses due to inflation. Price lagged cost by approximately 100 basis points in the quarter. Given the price increases we've implemented to date and future planned price increases and assuming no additional inflation, we expect to be ahead of the price-cost curve starting in the second half of the year. As a result of our combined cost, pricing, and supply chain actions, we anticipate operating margin improvement as the year progresses and year-over-year improvement. Non-GAAP adjusted EBITDA was 87.2 million for the fourth quarter, or 18.6% of net sales, down 260 basis points compared with Q4 of last year. This was driven primarily by the lower gross margins as a result of the slowdown in truck market in China and wind and COVID-related medical sales, as well as the price-cost dynamic and the expected higher SG&A expenses compared to a year ago. Interest expense for Q4 was up 151% year-over-year, driven by $32.1 million of incremental non-cash write-offs of deferred financing costs, debt discount, and the unrecognized amortization expenses associated with the interest rate swap settled, all related to the November refinancing. Please turn to slide 10 for a closer look at our balance sheet improvements, cash flow, and liquidity. Free cash flow for the quarter was $31.9 million compared with $91.3 million a year ago. We generated $176 million in free cash flow in 2021. Working capital was up $31.4 million or 10.9% from Q4 last year, primarily driven by an increase in inventory reflecting supply chain delays and inflationary pressures. Capital expenditures during the quarter totaled $15 million, up 60% from the prior year quarter as we continued to invest in growth opportunities. We ended the quarter with $246.1 million of cash. Since completing the ANS merger, we have paid down $465 million in term debt. In November, we completed a $1.4 billion refinancing of our term loan fee and revolving credit facility. In December, we borrowed $130 million under the new facility to finance our acquisition of NUC. And with that, our net leverage remains just under three times. Looking ahead, between our planned debt pay downs and the anticipated proceeds, assuming we close the sale of the JVS business, we expect to exit 2022 with leverage of approximately two times on a net debt basis, well within our target range. As a result of our November 2021 refinancing, We've reduced our interest costs by 50 basis points, which saves approximately $4.5 million annually at current debt levels, while also providing us with the ability to further reduce interest costs as we continue to de-lever. Upsizing to a $1 billion revolver, which incorporates acquisition holidays for leverage, provides us with greater flexibility to invest in organic growth and execute on our M&A strategy. Entering 2022, we will continue to manage our leverage positioning us for future investments and growth, both organically and through M&A, and supporting our quarterly dividend. Please turn to slide 11 to review our full year 2022 financial guidance. As we begin 2022, we're confident about Altra's prospects for the year. Although risks related to COVID, the supply chain, labor markets, and inflation remain elevated, we expect continued strength across most of our markets in a healthy 2022 from a revenue perspective. We're encouraged that we've been able to leverage our strong customer relationships to pursue opportunities to gain share by outperforming our competitors and meeting our customers' needs. Although the double-digit growth we saw in 2021 may not be sustainable, we're entering 2022 with more than $800 million in backlog and a book-to-bill ratio of 1.11. We're also encouraged by the performance of our business and our prospects for continued margin expansion. In addition to the record backlog, we're entering 2022 with pricing initiatives underway that we expect to flow through to the bottom line as the year unfolds. Although we expect to see continued challenges in the year ahead, especially during the first half of the year from labor shortages, transportation issues, and material shortages, the team has proactively managed these challenges thus far, and we expect to continue doing so. I would like to note that the 2022 guidance we're providing today includes the contributions of Nook Industries and JVS, which is currently treated as an asset held for sale. We intend to update our 2022 guidance upon closing of the JVS transaction, which we expect to complete in 2022. With that as background, our guidance for 2022 is as follows. Annual sales in the range of $2.025 to $2.065 billion. Gap diluted EPS in the range of $2.84 to $2.92 and non-gap diluted EPS in the range of $3.55 to $3.70. Non-gap adjusted EBITDA in the range of $410 to $425 million. Depreciation and amortization in the range of $100 to $110 million, lower than prior years due to the asset held for sale accounting treatment. capital expenditures expected in the range of $45 to $50 million, a normalized tax rate for the full year to be in the range of 21 to 23%, and adjusted non-GAAP free cash flow in the range of $200 to $225 million. I would like to note that we have provided a pro forma historical view of ultra excluding JVS as an appendix to our presentation slides. For purposes of our 2022 guidance, we have assumed JVS's contribution to be similar to their 2021 results. In summary, Altra delivered record revenues in earnings per share in 2021, and we believe we are well positioned to repeat that in 2022. Our team is working hard to mitigate higher costs through pricing and other tactics, and we continue to focus on our portfolio and driving profitable growth. I'll now turn the call over to Carl before we take your questions.
spk03: Thank you, Todd. We look forward to reporting our progress in 2022. Our incoming order rate remains very strong. We're working on initiatives to close the cost-price gap. We continue to develop innovative solutions for our customers, driving organic growth. We're executing on the synergies plan for the Nook acquisition, and we're leveraging the Altra business system to drive improvements across the entire company. I'm also very excited about the actions we're taking to improve the balance sheet which will enable us to advance our strategy to become an even higher value supplier to our customers and position Altra as a premier industrial company for the long term. With that, we'll now open up the call for questions. Candice?
spk01: Thank you. If you would like to ask a question, please press Start followed by 1 on your telephone keypad. If for any reason you would like to remove your question, please press Start followed by 2. Again, to ask a question, it is start followed by one. As a reminder, if you are using a speakerphone, please remember to pick up your handset before asking your question. Our first question comes from Brian Blair of Hopenheimen. Your line is now open. Please go ahead.
spk02: Thank you. Good morning, guys. Good morning, Brian. Today, dig in on your sales outlook a little bit. How's your team thinking about first versus second half growth rates given the influence of backlog, position, order of momentum early in the year and the timing of expected price realization? And then for the full year, what's contemplated for volume versus price contribution in the 5% to 7% organic outlook?
spk03: Yeah, Brian, I might have told you this before in one of our other conversations, but This is a period I've never experienced in my career where when the economy recovers and other economic recoveries always felt like we had much more control over our own destiny. But right now, we're really throttled by the supply chain, logistics, labor shortages, and we're working really hard to mitigate those and offset them. But that's really the throttle. So I think you'll see Q1. where, again, even so far in the quarter, the bookings have been outstanding, but just getting the capacity ramped up to be able to get those bookings out the door is really challenging. So I think that's the real throttle on the business. Now, if COVID starts to reduce, and you saw, at least yesterday, I saw that they're talking about increasing the number of international flights, which might free up logistics a little bit. If some of these challenges start to mitigate, we're starting to see a little bit better labor too. So some of these things start to mitigate. We think the back half of the year, we can start to work on that backlog.
spk08: Yeah, and then related to your question, Brian, about sort of the cadence throughout the year, the first half will be more challenging than the second half. And we expect Q1 to be similar to the Q4 run rates from a margin perspective. And then Q2 is where we'll start to see some of the pricing actions really starting to take hold and we'll start transitioning into those more typical margin ranges and then accelerating more in the second half of the year as the price increases fully take effect and we've worked through that $800 million backlog. And as it relates to volume versus price, we've got baked into our guidance between 300 and 325 basis points for price, and then the remainder of that is the volume.
spk02: Okay, that's very helpful. And for Nook Industries, how should we think about growth rates for the foreseeable future? Where are run rates margins, and what kind of margin have you factored into your deal model as synergies are realized? And I guess to think about that progression, Where is gross margin right now relative to Ultra? And the annualized synergies as they ramp, are they weighted to COGS or SG&A over the coming years?
spk08: Yeah, so related to NUC, it rolls up into our Thompson business. It has very similar margin profiles as Thompson, so I'd call it sort of fleet average for A&S. From a growth perspective, they're in that 5% to 7% range like the rest of the business. And the synergies, I think we said in our release previously, 6 million, so 15% of their top line in synergies. And we expect to get, I think, about a third of those in year one. and we expect those to start flowing to the bottom line sometime before the end of the second quarter.
spk02: Okay, appreciate the detail. And one more, if I may. I promise it's not a multi-parter. What are the expected net proceeds from the JVS sale? I'm just not sure what the tax basis is there.
spk08: Yeah, there's about $25 million worth of tax leakage on the JVS deal. So we're estimating netting about $285 million after deal fees and taxes.
spk02: Okay, understood. Thanks again, guys. Okay, thanks, Brian.
spk01: Thank you. Our next question comes from Jeff Hammond. of key bank capital markets. Your line is now open. Please go ahead.
spk04: Hey, good morning, guys.
spk03: Morning, Jeff.
spk04: Morning, Jeff. So just really want to dig in on the sequential margins. It looks like 3Q to 4Q revenues were kind of flat, and you had a pretty big dip. And just wondering, you know, how much is going to mix versus, you know, price-cost getting worse versus, you know, something else?
spk08: Yeah, so from Q3 to Q4, it didn't necessarily get worse. It shifted a little bit from a price-cost standpoint. We went from whack-a-mole, which is continuing on, and then we started seeing more pressure on the electronic side of things in the fourth quarter, and about half of the impact was from those electronics in the fourth quarter. We continue to believe that that's going to, continue into the first quarter. And we made a number of price increases during the fourth quarter, but those won't start to really kick in as we're working through that backlog in the first quarter. We expect somewhere around 75% of the backlog will have flushed through by the end of the second quarter. And that's why we believe that the second quarter is where we'll start seeing the margins expand as the pricing takes hold.
spk04: Okay, and price-cost in 1Q versus that 100 basis point headwind? I think it's going to be similar to that.
spk08: Yeah, I think it's going to be comparable.
spk04: Okay, and then back on seasonality, I guess normally you have kind of a stronger first half versus second half on the top line. Is Is that any different this year, just given all the moving pieces with supply chain, et cetera?
spk08: Yeah, it is going to be different this year. We expect it to, you know, continuing to ramp up through the third quarter and then sort of level out going into the fourth quarter. You know, again, dealing with the supply chain and labor issues, we're a little bit throttled in the first part of the year.
spk04: Okay, great. And then just last one on end markets. Any kind of moving pieces and trends outside of what you saw in 4Q and any big laggards or leaders within the growth outlook?
spk03: I think we're starting to see some projects get released in some of the later cycle markets, which is really encouraging. So we saw some really good mining projects that we booked and Q4 and are bidding on some really nice projects now. I think the oil and gas, which people held back on CapEx last year, whether that starts to free up a little bit is a question mark. And with what's going on in that market, the price of oil and all the disruption that's out there, we think there's a good chance that some of that will release some funding there. And then the infrastructure bill, you know, on the construction side and aggregate and other pieces, you know, we're really encouraged that that's going to have some real legs to it, too, and starting to see some free up. Markets like marine, which are typically late cycle, big, you know, expensive projects, those are amped up probably in the back half of last year. So there's some really encouraging signs, and the order book is just rock-solid. It's really, really good. Okay, great. Thanks, guys. Thank you.
spk01: Thank you. Our next question comes from Mike Halloran from Baird. Your line is now open. Please go ahead.
spk06: Hey, good morning, gentlemen. Maybe we could just talk a little about inventory level from two perspectives. One, how do you think channel inventory looks? And two, how are your inventories level looking and kind of how you're looking at expectations for both of those as you track through the year?
spk03: I'll take the distribution. I'll take our inventory. Yeah, I'll say in general, I'd say inventory levels, if people could get more, they would take it. And we're seeing most of it gets sold through. And I don't think that's just in the distribution channel. I think that's probably our OEM customers too. So hopefully, if things free up a little bit, we'll start to see a little bit of an inventory build and get some of that inventory put back in place.
spk08: Yeah, and then from our own internal standpoint, we've increased our inventory balances quite a bit during the year. I think, as Carl mentioned, we'd like to continue probably building that a bit more if we could get some key pieces to that because it is having an impact on our ability to ship to customers. I think the teams have done a really good job of managing it and trying to get inventory in to help secure some of the pricing that they have in their backlog as well, which has also driven up our inventory balances. Overall, we're not very concerned about our working capital. It's actually weathered quite well through the pandemic, especially on the AR and AP side, and the inventory will continue to support this really high demand levels that we're seeing.
spk06: Thanks for that. And then excluding the JVS business in China, maybe some thoughts on just the trend lines there. Obviously, you have really tough comps on the JVS side in the China business. How direct does it look?
spk08: Yeah, the other item was the PortisGad, the medical business, just outsized performance in the back half of 2020. And that had an impact. You know, wind was also tough for us this year, especially in China. And then, you know, we saw, you know, modest growth across the rest of the markets. When you look at the segments, you know, PTT grew faster. I think that partially is due to starting to see some activity in these later cycle markets. And, you know, the ANS side grew more modestly when you exclude JVS, which had a, you know, a big negative impact on it, you know, grew in the 3% range.
spk06: Thanks for that. One last one. We can get more out.
spk08: Yeah. I was going to say, if we could get more out, we could, you know, if we didn't have these constraints... the revenue on the ANS side would have been significantly higher.
spk06: That makes sense. Last one here, just on the M&A side. Obviously, you've got some moving pieces in the short term here. What's the pipeline look like, but what's the willingness to go after the pipeline ahead of the JVS close?
spk03: I think we're going to continue to build the pipeline and pay down debt through this year. And then once we close... the JVS transaction and, you know, really improve the balance sheet, that's when we're probably more likely to pull the trigger on something. We're at, you know, right around three now, and I think we've stated our goal is to be between two and three, so I'd prefer to get it down closer to two and work on the pipeline as we go through this. And that work is going really well. I think that's, you know, if you look at the Nook acquisition we did, the Thompson business was really involved in diligence and coming up with an integration plan and a plan. And historically, that would have been done by corporate. So we're trying to get the businesses more involved in developing the pipeline and then working on the deal once we get it going. So that's going really well. That's a nice, really nice change for us. Thanks, Carl. Thanks, Todd.
spk08: Thanks, Mike.
spk01: Mike? Thank you. As a reminder, if you would like to register a question, please press Start followed by 1 on your telephone keypad. If you'd like to remove your question for any reason, please press Start followed by 2. Our next question comes from Joel Tiss of BMO Capital Markets. Your line is now open. Please go ahead.
spk07: Hey, guys. How's it going?
spk03: Good, Joel. How are you?
spk07: Good, Joel. How are you?
spk03: Congratulations, Joel.
spk07: Oh, yeah. How much time left? Yeah. Well, now we won't have to be as confused with Christian and Christensen and all that kind of stuff. So you made it a little easier for us. Can you talk a little bit about the pricing and the backlog? And given how tight the markets are, is the pricing a little bit dilutive that's in the backlog? And given the tightness in the markets, is there an ability to adjust that? or you just want to be true to your customers and just push it through and worry about tomorrow?
spk08: Yeah, some of our backlog is going to be dilutive, which is why we believe Q1 is going to see similar margin levels as Q4 as we work through that. We are going after anywhere we can put in surcharges to at least cover the costs. We are pushing that. And we have repriced some of the backlog as well. But there is probably about half of it that is price exposed.
spk07: Okay. And then maybe this is an unfair question, but I want to ask it anyway. Any businesses or product lines that you guys are noticing that are maybe a little more commoditized? I mean, you probably have a good insight where they're pricing through. And maybe instead of calling out the businesses, maybe can you give us a sense – Would it be 10% of sales or 5% or you think that you've cleaned most of that out over the years?
spk03: And you broke up for part of the question where you said they're commoditized and trying to push price to it. I think I missed the key part of the question. Just broke up.
spk07: Yeah, just trying to figure out maybe what percent of revenues that you guys have noticed has been a little more difficult to get pricing through implying that the businesses have become commoditized.
spk03: Yeah, it's interesting, Joel. So even the components that I would say are more commodity-like in nature and where it's more price and availability, we're able to get price on those. Where we can't get price is where we have long-term contracts with customers and the big OEMs where you're kind of locked in with a multi-year contract. We're pushing through surcharges and going to the mat trying to get price, but that's probably where we have a harder, where it's more of a challenge. Some of the commodity products, we're actually doing quite well on pricing. Some of the things that are more commodity-like.
spk07: That leads into my last question. Can you talk a little bit about your focus on acquisitions? Where are there more reasonably priced areas or you know, that's less of a concern. You're more focused on trying to kind of enhance your competitiveness and find synergies and, you know, related product lines. Thank you.
spk03: Yeah, thanks, Joel. So where we're focused on looking is in those end markets that we think are going to have better secular growth trends. So automation, medical, aerospace and defense, robotics, yeah, automation. And we haven't seen anything that looks like it has a reasonable, at least in my history, the multiples now are just kind of stratospheric. So it's just shocking what some of the businesses are going for. But we do have a really good plan. And, again, I'm going to put a pitch in for our investor day because I think we're going to go through a lot of what the long-term strategy for the business is in those places where we want to grow and how we're growing, both organically and in our portfolio management where we want to build out through acquisition, I think will be much clearer and we'll have more time to spend on it on the investor day. So hopefully you can make it to the investor day.
spk07: All right. Well, thank you so much. Thanks, Joel. Thanks, Joel.
spk01: Thank you. There are no additional questions waiting at this time, so I'll pass the conference over to our management team for closing remarks.
spk03: Okay, thank you. And thank you again for joining us today. As a reminder, as I just put a pitch in, our Investor Day will be hosting that on March 8th in New York City, and we really hope you can join us. And that concludes today's call. Thank you.
spk01: Thank you. That concludes today's conference call. Thank you for your participation. You may now disconnect your line.
Disclaimer